A ClinicalTrials.gov registration states that participants with type 2 diabetes already on once-weekly semaglutide will switch to once-weekly CagriSema for about six months, with all participants receiving the tested treatment.
A registration describes a randomized study in children and adolescents with excess body weight comparing CagriSema, cagrilintide, semaglutide and placebo, with an optional open-label extension. No results are posted.
A ClinicalTrials.gov registration for CagriSema in people living with obesity describes a randomised placebo-controlled main phase followed by an extension in which all participants receive CagriSema. No results are posted.
A ClinicalTrials.gov registration describes a randomised comparison of CagriSema, cagrilintide, semaglutide and placebo in people with excess body weight, followed by a drug-free extension phase.
A ClinicalTrials.gov registration outlines a randomized, double-blind, placebo-controlled pilot trial of daily subcutaneous BPC-157 for 90 days after arthroscopic rotator cuff repair in twenty patients. No results are reported.
A review of rodent ischemia-reperfusion injury models summarizes reported effects of BPC 157 on oxidative, inflammatory and vascular markers, with no meta-analysis performed because of heterogeneity.
A systematic review and pairwise meta-analysis of eight randomized controlled trials in 6,898 adults reports larger body weight and HbA1c reductions with CagriSema than with semaglutide, cagrilintide, or placebo, alongside more adverse events.
A network meta-analysis of 58 randomised controlled trials in 24,214 adults with overweight or obesity without diabetes reports placebo-adjusted weight loss of -17.32% with CagriSema, behind retatrutide and tirzepatide.